Nyxoah SA (NAS:NYXH)
$ 8.255 -0.135 (-1.61%) Market Cap: 303.57 Mil Enterprise Value: 253.25 Mil PE Ratio: 0 PB Ratio: 2.52 GF Score: 59/100

Nyxoah SA at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 27, 2023 / 01:45PM GMT
Release Date Price: $7.12 (+0.28%)
Ross Osborn Cantor Fitzgerald;Analyst

Good morning. My name is Ross Osborn. I'm the medtech life science tools and diagnostics analyst at Cantor. And today, we have Olivier Taelman, CEO of Nyxoah.

Olivier Taelman Nyxoah SA;CEO

Thank you.

Ross Osborn Cantor Fitzgerald;Analyst

Thank you for being here. So starting off, would you just provide a brief background on yourself?

Olivier Taelman Nyxoah SA;CEO

Yes, brief background on myself. So as you can hear by my accent, I'm non-US. I'm coming from Belgium, Flemish speaking, studied biology, started working in the pharmaceutical industry for roughly 12 years. Eli Lilly was my first company, then Sanofi Aventis; switched into the medtech space, joining Medtronic. I was, for almost 11 years at Medtronic, always in neuromodulation, leading the European business.

After Medtronic, switched to Stryker Neurovascular, and then decided to leave the corporate life to go into the startup environment

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot